Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1141255

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Non-surgical Cosmetic Procedures: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners.
tabling member constituency	North Durham
tabling member printed	Mr Kevan Jones
uin	280927
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:32:36 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1438 label Biography information for Mr Kevan Jones

1141380

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280998
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:35:38 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1141381

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280999
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:38:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1141399

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Speech and Language Therapy: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the report of the Children's Commissioner entitled, We need to talk: Access to speech and language therapy, published in June 2019, what plans he has to ensure that expenditure data is collected on the support local areas provide for children and young people with speech, language and communication needs.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	281095
answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>The Department is keen to work with the Children’s Commissioner’s Office and other partners on options for producing expenditure data on speech, language and communication services. Officials will discuss this matter at the next available opportunity.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/07/2019 11:45:16 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4603 label Biography information for Preet Kaur Gill

1141473

registered interest
date	23/07/2019
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Wills: VAT
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what assessment he has made of the potential merits of removing VAT from wills that include a charitable donation.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	280957
answer	answer is ministerial correction date of answer 26/07/2019 answer text <p>Under current EU law, it is not possible to remove VAT on fees for writing wills where those wills include charitable donations.</p> answering member constituency Hereford and South Herefordshire answering member printed Jesse Norman question first answered 26/07/2019 10:19:44 answering member 3991 label Biography information for Jesse Norman
tabling member	1436 label Biography information for Paul Farrelly